Point-of-Care Lung Ultrasound Predicts Severe Disease and Death Due to COVID-19: A Prospective Cohort Study

• Published in: Critical care explorations 2022-08, Vol.4 (8), p.e0732-e0732
• Main Authors: Blair, Paul W, Siddharthan, Trishul, Liu, Gigi, Bai, Jiawei, Cui, Erja, East, Joshua, Herrera, Phabiola, Anova, Lalaine, Mahadevan, Varun, Hwang, Jimin, Hossen, Shakir, Seo, Stefanie, Sonuga, Olamide, Lawrence, Joshua, Peters, Jillian, Cox, Andrea L, Manabe, Yukari C, Fenstermacher, Katherine, Shea, Sophia, Rothman, Richard E, Hansoti, Bhakti, Sauer, Lauren, Crainiceanu, Ciprian, Clark, Danielle V
• Format: Article
• Language: English
• Subjects: Observational Study
• ISSN: 2639-8028; 2639-8028
• DOI: 10.1097/CCE.0000000000000732

The clinical utility of point-of-care lung ultrasound (LUS) among hospitalized patients with COVID-19 is unclear. Prospective cohort study. A large tertiary care center in Maryland, between April 2020 and September 2021. Hospitalized adults (≥ 18 yr old) with positive severe acute respiratory syndrome coronavirus 2 reverse transcriptase-polymerase chain reaction results. None. All patients were scanned using a standardized protocol including 12 lung zones and followed to determine clinical outcomes until hospital discharge and vital status at 28 days. Ultrasounds were independently reviewed for lung and pleural line artifacts and abnormalities, and the mean LUS Score (mLUSS) (ranging from 0 to 3) across lung zones was determined. The primary outcome was time to ICU-level care, defined as high-flow oxygen, noninvasive, or invasive mechanical ventilation, within 28 days of the initial ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the median age was 61 years and 114 participants (43.2%) were female. The median mLUSS was 1.0 (interquartile range, 0.5-1.3). Following enrollment, 27 participants (10.0%) went on to require ICU-level care, and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at enrollment was associated with disease progression to ICU-level care (adjusted hazard ratio [aHR], 3.61; 95% CI, 1.27-10.2) and 28-day mortality (aHR, 3.10; 95% CI, 1.29-7.50). Pleural line abnormalities were independently associated with disease progression to death (aHR, 20.93; CI, 3.33-131.30). Participants with a mLUSS greater than or equal to 1 or pleural line changes on LUS had an increased likelihood of subsequent requirement of high-flow oxygen or greater. LUS is a promising tool for assessing risk of COVID-19 progression at the bedside.